Abstract
There are several pharmacogenetic decision support tools that have been evaluated in clinical settings, but the evidence for such testing in clinical practice is insufficient, particularly when it comes to predicting side effects of medications, researchers write in a recent issue of the American Journal of Psychiatry which can be taken as an object lesson for the substance use disorder (SUD) field, which is ripe for promotion of such tools, especially in alcohol use disorders. There have been substantial investigations into genetic variants associated with major depressive disorder, and gene‐drug interactions affecting medication response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
